Long-acting co-agonists of the glucagon and GLP-1 receptors
Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
1. A GCG/GLP-1 receptor co-agonist peptide comprising the formula
(SEQ ID NO: 123)
HX 2 QGTFTSX 9 X 10 SLYLDX 16 RAAX 20 X 21 FVX 24 X 25 LX 27 X 28 TX 30 -NH 2
or a pharmaceutically acceptable salt or counterion thereof, wherein
X 2 is alpha-aminoisobutyric acid (aib), D-Ser, or alpha-Methyl-L-Serine (alpha-MS);
X 9 is Asp, or Glu;
X 10 is Lys or p-aminomethyl-L-phenylalanine (pAF) conjugated to a fatty acid provided that the amino acid at position 20 or 24 is a Lys conjugated to a fatty diacid, or Tyr;
X 16 is aib, Ala, Ser, or Glu;
X 20 is Lys is conjugated to a fatty diacid, pAF conjugated to a fatty diacid, norleucine (Nle) conjugated to a fatty diacid, or Gln;
X 21 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Asp, alpha-methyl-L-phenylalanine (alpha-MF), or alpha-MD;
X 24 is Gln, Lys conjugated to a fatty diacid, or pAF conjugated to a fatty diacid;
X 25 is Trp or alpha-methyl-L-tryptophan (alpha-MW);
X 27 is L-Met sulphone or Leu;
X 28 is Glu, Asp, alpha-MD, Lys, aib, Ala, Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid;
X 30 is absent, or Lys linked at the C-terminus to gamma-Glu when X 27 is Leu or L-Met-sulphone and X 28 is Ala, aib, alpha-MD, or Lys conjugated to a fatty diacid;
with the proviso that for each co-agonist peptide only one of X 10 , X 20 , X 21 , X 24 , or X 28 is conjugated to a fatty diacid; and wherein
the GCG/GLP-1 receptor co-agonist peptide comprises at:
1) X 10 a Lys conjugated to a C16 fatty acid and a Lys at position 20 or 24 conjugated to a fatty diacid;
2) X 20 a pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid;
3) X 21 a pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid;
4) X 24 a pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid; or
5) X 28 a pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid.
2. The GCG/GLP-1 receptor co-agonist peptide of claim 1 , wherein the fatty diacid comprises a C14, C15, C16, C17, C18, C19, or C20 fatty diacid.
3. The GCG/GLP-1 receptor co-agonist peptide of claim 1 , wherein the GCG/GLP-1 receptor co-agonist peptide comprises the fatty diacid conjugated to Lys or pAF via a gamma-Glu linker.
4. The GCG/GLP-1 receptor co-agonist peptide of claim 1 , wherein the GCG/GLP-1 receptor co-agonist peptide comprises the fatty diacid conjugated to Lys or pAF via a PEG 2 PEG 2 -gamma-Glu linker wherein PEG 2 is 8-amino-3,6-dioxaoctanoic acid.
5. The GCG/GLP-1 receptor co-agonist peptide of claim 1 , wherein the GCG/GLP-1 receptor co-agonist peptide comprises at X 10 a pAF conjugated to a fatty diacid.
6. The GCG/GLP-1 receptor co-agonist peptide of claim 1 , wherein the GCG/GLP-1 receptor co-agonist peptide has activity at the glucagon receptor and the GLP-1 receptor.
7. A composition comprising one or more of the GCG/GLP-1 receptor co-agonist peptides of claim 1 , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. A method for treating a patient for a metabolic disease or disorder comprising administering to a patient in need thereof an effective amount of one or more of the GCG/GLP-1 receptor co-agonist peptides of claim 1 to treat the metabolic disease or disorder in the patient, wherein the metabolic disease or disorder comprises diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.
9. The method of claim 8 , wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.
10. The method of claim 8 , wherein the patient has more than one metabolic disease or disorder.
11. The method of claim 8 , wherein the metabolic disease or disorder comprises (i) diabetes and NASH, NAFLD, or obesity; (ii) obesity and NASH or NAFLD; (iii) diabetes, NASH, and obesity; (iv) diabetes, NAFLD, and obesity; or (v) diabetes and obesity.
12. A method for treating a patient for a metabolic disease or disorder comprising administering to the patient in need thereof an effective amount of the composition of claim 7 to treat the metabolic disease or disorder in the patient, wherein the metabolic disease or disorder comprises diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.
13. The method of claim 12 , wherein the patient has more than one metabolic disease or disorder.
14. The method of claim 12 , wherein the metabolic disease or disorder comprises (i) diabetes and NASH, NAFLD, or obesity; (ii) obesity and NASH or NAFLD; (iii) diabetes, NASH, and obesity; (iv) diabetes, NAFLD, and obesity; or (v) diabetes and obesity.
15. A method for treating a metabolic disease or disorder in a patient or individual comprising administering to the patient or individual in need thereof an effective amount of a composition comprising a co-agonist peptide agonist of claim 1 and administering to the patient or individual an effective amount of a composition comprising an insulin or insulin analog to treat the metabolic disease or disorder in the patient or individual wherein the metabolic disease or disorder comprises diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.
16. The method of claim 15 , wherein the insulin analog comprises insulin detemir, insulin glargine, insulin glulisine, insulin degludec, or insulin lispro.
17. The method of claim 15 , wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.
18. The method of claim 15 , wherein the patient has more than one metabolic disease or disorder selected from (i) diabetes and NASH, NAFLD, or obesity; (ii) obesity and NASH or NAFLD; (iii) diabetes, NASH, and obesity; (iv) diabetes, NAFLD, and obesity; or (v) diabetes and obesity.
19. A GCG/GLP-1 receptor co-agonist peptide comprising the formula
(SEQ ID NO: 105)
HX 2 QGTFTSDX 10 SLYLDX 16 RAAX 20 X 21 FVX 24 X 25 LX 27 X 28 TX 30 -NH 2
wherein
X 2 is alpha-aminoisobutyric acid (aib), D-Ser, or alpha-Methyl-L-Serine (alpha-MS);
X 9 is Asp or alpha-Methyl-L-Aspartic acid (alpha-MD);
X 10 is Lys or p-aminomethyl-L-phenylalanine (pAF) conjugated to a fatty acid provided that the amino acid at position 20 or 24 is a Lys conjugated to a fatty diacid, or Tyr;
X 16 is aib, Ala, Ser, or Glu;
X 20 is Lys is conjugated to a fatty diacid, pAF conjugated to a fatty diacid, norleucine (Nle) conjugated to a fatty diacid, or Gln;
X 21 is Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid, Asp, alpha-methyl-L-phenylalanine (alpha-MF), or alpha-MD;
X 24 is Gln, Lys conjugated to a fatty diacid, or pAF conjugated to a fatty diacid;
X 25 is Trp or alpha-methyl-L-tryptophan (alpha-MW);
X 27 is L-Met sulphone or Leu;
X 28 is Glu, Asp, alpha-MD, Lys, aib, Ala, Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid; and
X 30 is absent or Lys linked at the C-terminus to gamma-Glu when X 27 is Leu or L-Met-sulphone and X 28 is Ala, aib, alpha-MD, or Lys conjugated to a fatty diacid;
with the proviso that for each co-agonist peptide, only one of X 10 , X 20 , X 21 , X 24 , or X 28 is conjugated to a fatty diacid.
20. A GCG/GLP-1 receptor co-agonist peptide wherein the GCG/GLP-1 receptor co-agonist peptide is selected from the group consisting of SEQ ID No. NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, and SEQ ID NO: 104, or a pharmaceutically acceptable salt or counterion thereof.
21. A GCG/GLP-1 receptor co-agonist peptide wherein the GCG/GLP-1 receptor co-agonist peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID No. NO: SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, and SEQ ID NO: 104, or a pharmaceutically acceptable salt or counterion thereof.
22. A GCG/GLP-1 receptor co-agonist peptide comprising the formula
(SEQ ID NO: 106)
HX 2 QGTFTSDX 10 SLYLDX 16 RAAX 20 X 21 FVX 24 X 25 LX 27 X 28 T-NH 2
wherein
X 2 is alpha-aminoisobutyric acid (aib), D-Ser, or alpha-Methyl-L-Serine (alpha-MS);
X 9 is Asp or alpha-Methyl-L-Aspartic acid (alpha-MD);
X 10 is Lys or p-aminomethyl-L-phenylalanine (pAF) conjugated to a fatty acid provided that the amino acid at position 20 or 24 is a Lys conjugated to a fatty diacid, or Tyr;
X 16 is aib, Ala, Ser, or Glu;
X 20 is Lys is conjugated to a fatty diacid, pAF conjugated to a fatty diacid, norleucine (Nle) conjugated to a fatty diacid, or Gln;
X 21 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Asp, alpha-methyl-L-phenylalanine (alpha-MF), or alpha-MD;
X 24 is Gln, Lys conjugated to a fatty diacid, or pAF conjugated to a fatty diacid;
X 25 is Trp or alpha-methyl-L-tryptophan (alpha-MW);
X 27 is L-Met sulphone or Leu; and
X 28 is Glu, Asp, alpha-MD, Lys, aib, Ala, Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid;
with the proviso that for each co-agonist peptide only one of X 10 , X 20 , X 21 , X 24 , or X 28 is conjugated to a fatty diacid.
23. A GCG/GLP-1 receptor co-agonist peptide comprising the formula
(SEQ ID NO: 107)
HX 2 QGTFTSDX 10 SLYLDX 16 RAAX 20 X 21 FVX 24 X 25 LX 27 X 28 T-NH 2
wherein
X 2 is alpha-aminoisobutyric acid (aib);
X 9 is Asp or alpha-Methyl-L-Aspartic acid (alpha-MD);
X 10 is Lys or p-aminomethyl-L-phenylalanine (pAF) conjugated to a fatty acid provided that the amino acid at position 20 or 24 is a Lys conjugated to a fatty diacid, or Tyr;
X 16 is aib, Ala, Ser, or Glu;
X 20 is Lys is conjugated to a fatty diacid, pAF conjugated to a fatty diacid, norleucine (Nle) conjugated to a fatty diacid, or Gln;
X 21 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Asp, alpha-methyl-L-phenylalanine (alpha-MF), or alpha-MD;
X 24 is Gln, Lys conjugated to a fatty diacid, or pAF conjugated to a fatty diacid;
X 25 is Trp or alpha-methyl-L-tryptophan (alpha-MW);
X 27 is L-Met sulphone or Leucine;
X 28 is Glu, Asp, alpha-MD, Lys, aib, Ala, Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid; and
X 30 is absent or Lys linked at the C-terminus to gamma-Glu when X 27 is Leu or L-Met-sulphone, and X 28 is Ala, aib, alpha-MD, or Lys conjugated to a fatty diacid;
with the proviso that for each co-agonist peptide, only one of X 10 , X 20 , X 21 , X 24 , or X 28 is conjugated to a fatty diacid and excludes peptides disclosed in Table 1 of WO2017074798.
24. A GCG/GLP-1 receptor co-agonist peptide wherein the GCG/GLP-1 receptor co-agonist peptide is selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 120, SEQ ID NO: 121, and SEQ ID NO: 122.